Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Data were acquired in real-time using the DatLab 7 software
Rarely, severe side effects have been reported, such as pancreatitis, medullary thyroid cancer, acute (sudden) kidney injury, and worsening diabetes-related retinopathy
Novo Nordisk is in control of GLP-1s such as: Ozempic, Wegovy, Rybelsus and Victoza
More gas accumulates
Additional TRIUMPH and Other Phase 3 Trials Lilly has initiated or announced additional Phase 3 trials for retatrutide: Chronic low back pain -- Phase 3 initiated in Q3 2025 Overweight/obesity (additional) -- new Phase 3 trial initiated in Q3 2025 MASLD master protocol (NCT07165028) -- a Phase 3 multi-agent master protocol in MASLD that includes retatrutide (not a dedicated retatrutide-only liver trial), building on the Phase 2 liver fat sub-study TRANSCEND Program -- Type 2 Diabetes TRANSCEND Phase 3 program evaluating retatrutide specifically for type 2 diabetes
US$ 28.84
US$ 26.57
US$ 28.03
US$ 28.26
US$ 28.07
US$ 23.45
US$ 29.09
